ebc-46 and Melanoma

Tigilanol tiglate, a short-chain diterpene ester, is being developed as intratumoral treatment of a broad range of cancers. We conducted the first-in-human study of intratumoral tigilanol tiglate in patients with solid tumors.. Tigilanol tiglate was administered in a multicentre, non randomized, single-arm study, with escalating doses beginning with 0·06 mg/m. Twenty-two patients were enrolled. The maximum dose was 3·6 mg/m. Intratumoral tigilanol tiglate was generally well tolerated, the maximum tolerated dose was not reached, and clinical activity was observed in 9 tumor types including complete response in four patients. These results support the continued development of tigilanol tiglate for intratumoral administration.. QBiotics Group Limited Brisbane, Queensland, Australia was the sponsor of the study.

Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Diterpenes; Drug Monitoring; Female; Humans; Injections, Intralesional; Male; Melanoma; Middle Aged; Neoplasm Staging; Neoplasms; Treatment Outcome